Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease.
Int J Neurosci
; 127(5): 454-458, 2017 May.
Article
en En
| MEDLINE
| ID: mdl-27323891
ABSTRACT
BACKGROUND:
A decreased plasma level of soluble form of the receptor for advanced glycation end products (sRAGE) in patients with Alzheimer's disease (AD) has been reported. However, no evidence has shown whether the sRAGE plasma level of AD patients may differentiate from other types of dementia.METHODS:
Our study assessed sRAGE concentrations in the following 121 individuals in Chongqing area 36 patients with AD, 12 with vascular dementia (VaD), 14 with mixed dementia (MD), 24 with other dementia (OD) including Parkinson's disease dementia, frontotemporal dementia, paralytic dementia and 35 cognitively normal controls. The total plasma level of sRAGE was determined using sandwich ELISA method.RESULTS:
sRAGE concentration in AD is significantly decreased compared with healthy controls. However, the receiver operating characteristic curve analysis of sRAGE between the AD and the control shows a low diagnostic accuracy.CONCLUSIONS:
Our results demonstrate that sRAGE may assist the diagnosis of AD from normal individuals, but cannot differentiate AD from VaD, MD or OD.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Productos Finales de Glicación Avanzada
/
Enfermedad de Alzheimer
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Int J Neurosci
Año:
2017
Tipo del documento:
Article
País de afiliación:
China